New lipid-lowering drugs: an update

Authors


  • Disclosures ASW served on the advisory board for Amsterdam Molecular Therapeutics from 2006 to 2008 and has received lecture honoraria from Aegerion Pharmaceuticals (2008). He has been an investigator on clinical trials for AstraZeneca, Merck Sharp & Dohme, and Novartis. AV and DM have received lecture honoraria, travel funds and commercial clinical trial support from AstraZeneca, Boehringer-Ingelheim, Merck Sharp & Dohme, and Takeda. TH is managing director of a commercial medical writing company but received no commission for this work.

Dr A. S. Wierzbicki,
Department of Chemical Pathology,
St. Thomas’ Hospital,
Lambeth Palace Road,
London SE1 7EH, UK
Tel.: 0171 928 9292ext2027
Fax: 0171 928 4226
Email: anthony.wierzbicki@kcl.ac.uk

Summary

Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipoprotein cholesterol, for example, thyroid mimetics (thyroid receptor beta-agonists), antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, for example, novel peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase-1 inhibitors and high-density lipoprotein cholesterol (HDL-C), for example, mimetic peptides; HDL delipidation strategies and cholesterol ester transfer protein inhibitors and modulators of inflammation, for example, phospholipase inhibitors. Gene therapy for specific rare disorders, for example, lipoprotein lipase deficiency using alipogene tiparvovec is also in clinical trials. Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments as possible synergies exist between new and established compounds for the treatment of atherosclerosis.

Ancillary